Insider Selling: SiBone (NASDAQ:SIBN) CFO Sells $373,621.30 in Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 18,542 shares of SiBone stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $20.15, for a total transaction of $373,621.30. Following the transaction, the chief financial officer directly owned 185,231 shares in the company, valued at $3,732,404.65. This represents a 9.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, November 25th, Anshul Maheshwari sold 100 shares of SiBone stock. The shares were sold at an average price of $20.00, for a total transaction of $2,000.00.
• On Friday, November 21st, Anshul Maheshwari sold 1,200 shares of SiBone stock. The stock was sold at an average price of $20.01, for a total transaction of $24,012.00.
• On Monday, November 17th, Anshul Maheshwari sold 3,460 shares of SiBone stock. The stock was sold at an average price of $17.43, for a total transaction of $60,307.80.
• On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The shares were sold at an average price of $18.33, for a total transaction of $47,676.33.
• On Thursday, October 2nd, Anshul Maheshwari sold 3,311 shares of SiBone stock. The stock was sold at an average price of $14.20, for a total value of $47,016.20.

SiBone Stock Performance

Shares of SIBN opened at $20.38 on Monday. The stock has a 50 day moving average of $17.42 and a 200 day moving average of $16.85. The company has a market capitalization of $884.31 million, a price-to-earnings ratio of -39.96 and a beta of 0.76. SiBone has a 12 month low of $12.49 and a 12 month high of $20.80. The company has a current ratio of 7.97, a quick ratio of 6.62 and a debt-to-equity ratio of 0.21.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $48.66 million during the quarter, compared to the consensus estimate of $46.67 million. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%. As a group, sell-side analysts forecast that SiBone will post -0.78 earnings per share for the current year.

SiBone News Roundup

Here are the key news stories impacting SiBone this week:

• Positive Sentiment: Canaccord raised its price target on SIBN from $26 to $27 and maintained a Buy rating, signaling stronger upside expectations that support further upside for the shares. Read More.
• Positive Sentiment: Truist increased its price target from $21 to $23 and kept a Buy rating, adding incremental broker support for the stock’s near-term rally. Read More.
• Positive Sentiment: Needham published a bullish forecast calling for strong price appreciation for SIBN, adding another institutional voice to the buy-side narrative. Read More.
• Positive Sentiment: Market headlines reported SIBN trading up roughly 5.4% after analyst upgrades, reflecting immediate market reaction to the research updates and lifting momentum. Read More.
• Negative Sentiment: CFO Anshul Maheshwari sold 18,542 shares at an average price of $20.15 (total ~$373,621); the filing shows his holding decreased about 9.1%. Insider selling can raise short-term concern about insider conviction, even if sales are for personal reasons. Read More.
• Negative Sentiment: SVP Michael A. Pisetsky sold 19,600 shares at an average of $20.15 (total ~$394,940); his position fell ~7.8% after the trade. Multiple insider disposals the same day can amplify investor caution. Read More.

Institutional Trading of SiBone

A number of institutional investors have recently modified their holdings of the business. State of Alaska Department of Revenue purchased a new position in SiBone in the 3rd quarter valued at approximately $39,000. State of Wyoming bought a new position in shares of SiBone in the second quarter worth $55,000. Canada Pension Plan Investment Board bought a new position in shares of SiBone in the second quarter worth $68,000. Virtus Advisers LLC purchased a new position in shares of SiBone in the first quarter valued at $58,000. Finally, Quarry LP grew its position in shares of SiBone by 862.6% in the third quarter. Quarry LP now owns 4,861 shares of the company’s stock valued at $72,000 after purchasing an additional 4,356 shares in the last quarter. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SIBN has been the topic of a number of research analyst reports. Needham & Company LLC boosted their target price on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Truist Financial lifted their price target on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday. Canaccord Genuity Group upped their price objective on SiBone from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Wednesday. Morgan Stanley increased their price objective on SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of SiBone in a research note on Monday, December 15th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, SiBone currently has an average rating of “Moderate Buy” and a consensus target price of $25.00.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.